Iktos
Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.
Iktos is one of the few genuinely end-to-end DMTA platforms that couples generative design (Makya) with retrosynthesis (Spaya) and physical automation (Iktos Robotics, now integrated more deeply with Chemspeed). The 2026 additions make it more programmable than it was: Iktos Engine exposes APIs for agentic workflows and computational chemistry pipelines, so teams can script Makya and Spaya into existing pipelines rather than treating the suite as a standalone desktop tool. It suits well-resourced pharma and biotech groups working on PPIs, molecular glues and PROTACs, where multi-parametric optimisation and 3D constraints matter more than raw molecule count. It does not suit academic labs
Verified 1d ago · liveness 66/100 · cite: rightaichoice.com/tools/iktos
- Large pharma groups running full DMTA automation with AI and robotics
- Medicinal chemistry teams targeting PPIs, molecular glues or PROTACs
- Organisations aiming to compress discovery timelines below two years
- Computational chemistry groups that need generative design tied to proven synthetic accessibility
- Academic labs or small biotechs without capital for enterprise robotics
- Teams that only need retrosynthesis and no automation — Spaya standalone is the narrower fit
- Researchers working on biologics, antibodies or gene therapies
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Iktos if you want AI retrosynthesis without committing to lab automation — Spaya standalone covers route planning, while Makya plus Iktos Robotics is a programme-level investment in hardware and chemistry teams.
Robotic synthesis and analysis runs on physical hardware that has to be installed, maintained and fed consumables, so the automation side carries lab operating costs beyond any software line item.
Iktos is scoped for well-funded pharma, biotech and academic groups running multi-target discovery programmes — the kind of organisation that can absorb robotic lab infrastructure and dedicated chemistry headcount. It is not priced or structured against self-serve cheminformatics tools that a single computational chemist buys on a card; those cover retrosynthesis or molecule generation alone, without the automated DMTA loop. Expect the commercial conversation to be programme-level and shaped
In short
Iktos — Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery. Best for Large pharma groups running full DMTA automation with AI and robotics, Medicinal chemistry teams targeting PPIs, molecular glues or PROTACs, Organisations aiming to compress discovery timelines below two years. Contact Sales pricing.
No head-to-head comparison for Iktos yet — the alternatives below are the closest matches we list.
What people actually say about Iktos — is it worth it?
We scanned public community sources for Iktos on Oct 9, 2026 and could not establish that the discussion we found is about this tool rather than something else sharing its name. Only 0 of the posts we fetched could be positively tied to Iktos. Rather than publish a sentiment score built on the wrong subject, we publish nothing here and re-run the scan.
Viability Score
How well maintained and how widely used is Iktos? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →Key Features
- Generative AI for de novo small-molecule design (Makya)
- Synthetic accessibility optimisation built into molecule generation
- Multi-parametric optimisation across multiple project objectives
- 3D constraint inclusion during molecular design
- Makya 2.0 data analysis and visualisation experience
- AI-driven retrosynthesis with real-time route display (Spaya)
- Customisable retrosynthesis steps and constraints
- Integration with external data providers for route validation
- Automated chemical synthesis and analysis (Iktos Robotics Chemistry)
- Workflow management and raw material ordering
- High-throughput data generation and DMTA iteration
- Purification automation (ongoing integration)
- Multidimensional biological data from imaging platform
- In-cellulo screening for protein-protein and RNA-protein interactions
- Iktos Engine APIs for agentic workflows and computational chemistry pipelines
About Iktos
Iktos is a drug-discovery platform built around three components: Makya, a generative AI SaaS for de novo small-molecule design; Spaya, an AI-driven retrosynthesis engine; and Iktos Robotics, an automated Design-Make-Test-Analyze (DMTA) system. Makya designs diverse, medchem-like molecules with a chemistry-driven approach that emphasises synthetic accessibility, multi-parametric optimisation against multiple project objectives, and the inclusion of 3D constraints. Spaya converts target compounds into commercially available starting materials by displaying feasible retrosynthetic routes in real time, with customisable steps and constraints. Iktos Robotics handles workflow management, raw-material ordering, synthesis, purification and analysis, while a biology arm uses multidimensional in-cellulo imaging data to guide Makya toward small-molecule modulators of protein-protein interactions, RNA-protein interactions, protein-protein self-assembly, molecular glues and PROTACs. Since 2016, Iktos says it has run more than 60 collaborations with pharma, biotech and academic groups, and it maintains an in-house pipeline across targets including MTHFD2 (inflammation and autoimmune diseases), the amylin receptor (obesity and metabolism) and SKP2-CKS1 (immuno-oncology). A 2026 partnership with Chemspeed deepens the robotic integration, and the 2026 release of Iktos Engine exposes APIs for agentic workflows and computational chemistry pipelines. The platform is aimed at well-funded medicinal-chemistry and computational-chemistry teams pursuing hard targets and willing to invest in lab infrastructure; access is arranged through Iktos directly.
Behind the Verdict
The honest framing: Iktos is not a SaaS subscription you buy on a credit card. It is a drug-discovery programme partner with a software layer on top. Makya is the software core — a generative model designed by chemists, and marketed on the axis that actually matters to a medicinal chemist: synthetic accessibility rather than sheer novelty of output. That, plus multi-parametric optimisation and 3D constraint handling, is the part a competitor would have to reproduce and cannot do with a generic LLM and a prompt. Spaya is the more broadly accessible piece: retrosynthesis with a real-time route display, customisable step counts and constraints, and integration with external data providers for route validation. For a computational chemistry team without robotics, Spaya is the low-risk entry point. Where Iktos stands apart is the physical loop. Iktos Robotics closes design-make-test-analyse with automated synthesis, purification, analysis and high-throughput iteration, and the biology platform feeds multidimensional in-cellulo imaging data back into Makya — so optimisation is driven by measured activity in relevant cellular environments, not just docking scores. The stated goal of sub-two-year discovery timelines rests on that closed loop, not on the AI alone. Weaknesses and honest caveats. Full value is gated on hardware: the automated synthesis side depends on robotic systems and on your lab being able to accept them, so the timeline claim is not something a software-only user should expect. The published focus is small molecules; there is nothing here for antibodies, biologics or gene therapy teams. Commercial terms are handled directly with Iktos rather than self-serve, so budgeting starts with a conversation. And the in-house pipeline at MTHFD2, the amylin receptor and SKP2-CKS1 is worth reading carefully — it demonstrates the technology on Iktos' own targets, but it is Iktos' pipeline, not a customer outcome. Recent direction is clear: Iktos is pushing toward programmability. Iktos Engine (May 2026) exposes APIs for agentic workflows and computational chemistry pipelines, which matters if you want Makya and Spaya called from your own orchestration rather than through a UI. The Chemspeed partnership (March 2026) strengthens the robotic backbone. The MTHFD2 patent publication in July 2026 is a signal of internal research depth rather than a customer-facing feature, and you should read it as such.
Researching Iktos? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Iktos actually fits — and what changes day-one when you adopt it.
Starts a hit-to-lead campaign on a kinase target by generating novel scaffolds in Makya with multi-parametric optimisation and 3D constraints, then sends the shortlist to Spaya to check that each candidate has a feasible route from commercially available starting materials before any compound is ordered.
Outcome: A ranked, synthetically plausible compound set reaches the medicinal chemists without a round of dead-end designs that could never be made.
Uses Makya guided by multidimensional in-cellulo imaging data to design small-molecule modulators of the PPI, then routes the best designs through Iktos Robotics for automated synthesis, purification and analysis, iterating on measured activity rather than predicted affinity alone.
Outcome: The DMTA loop turns faster because synthesis and testing are queued automatically, and each cycle's measured biology data feeds the next round of design.
Wires Makya and Spaya into the company's existing pipeline orchestration through Iktos Engine APIs, so generative design and retrosynthesis run as programmatic steps alongside internal tools rather than through a standalone interface.
Outcome: Iktos becomes a callable component in the discovery stack, and the team avoids maintaining a parallel manual workflow for generative design.
Use Cases
- Design novel, synthetically accessible drug candidates with generative AI and validate them through automated synthesis
- Plan efficient retrosynthetic routes from a target compound back to commercially available starting materials in Spaya
- Automate the DMTA cycle for hit-to-lead and lead optimisation using robotic synthesis, purification and testing
- Identify small-molecule modulators of protein-protein interactions, RNA-protein interactions, molecular glues and PROTACs
- Call Makya and Spaya programmatically via Iktos Engine APIs from an existing computational chemistry pipeline
- Feed multidimensional in-cellulo imaging data back into generative design to optimise molecular properties across cycles
Models Under the Hood
as of 2026-10-16
Limitations
- Makya and Spaya are purpose-built for small-molecule drug discovery rather than general-purpose AI, and the automated DMTA workflow depends on Iktos Robotics hardware being installed in your lab.
- The advertised sub-two-year discovery timeline assumes that robotic hardware is in place; software alone does not deliver the full loop.
- Commercial terms and the Iktos Engine API access are arranged directly with Iktos rather than published, so budget and scope are set in a conversation.
as of 2026-09-29
Verification history
We have re-verified Iktos 20 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 20 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Iktos's pricing actually pencils out — and where peers do it cheaper.
Iktos is scoped for well-funded pharma, biotech and academic groups running multi-target discovery programmes — the kind of organisation that can absorb robotic lab infrastructure and dedicated chemistry headcount. It is not priced or structured against self-serve cheminformatics tools that a single computational chemist buys on a card; those cover retrosynthesis or molecule generation alone, without the automated DMTA loop. Expect the commercial conversation to be programme-level and shaped
Setup time & first value
How long it actually takes to get something useful out of Iktos — broken out by persona, not the marketing-page minute.
For a computational chemistry team adopting Makya and Spaya as software, expect onboarding measured in weeks, mostly spent configuring project objectives, constraints and data sources. For organisations adding Iktos Robotics, add the physical side: hardware installation, integration with existing lab systems and qualification of automated synthesis and analysis, which extends first-value time to
Switching to or from Iktos
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From manual medicinal chemistry design cycles: replace spreadsheet-and-docking iteration with Makya generative design plus Spaya route checking before compounds are ordered.
- →From standalone retrosynthesis tools: consolidate route planning into Spaya so retrosynthetic output stays consistent with the generative design stage and, where installed, with Iktos Robotics.
- →From in-house generative models: move de novo design onto Makya to gain synthetic accessibility optimisation, multi-parametric optimisation and 3D constraint handling in one place.
- →From disconnected synthesis vendors: bring synthesis and analysis in-house via Iktos Robotics so DMTA data returns directly to the design model.
- ↗To stand-alone generative chemistry tools: if you leave the automation loop behind, Makya and Spaya output has to be re-integrated into a design pipeline you maintain yourself.
- ↗To contract research organisations: teams without robotic infrastructure can route synthesis and testing to a CRO, trading turnaround time for lower capital commitment.
- ↗To broader discovery informatics suites: consolidating on a larger data platform can make sense if your priority shifts to enterprise-wide data management rather than generative design plus automation.
Integrations
Resources & Guides
Tutorials & Learning
YouTube returned 6 videos for “Iktos”, and we withheld 6: 6 could not be judged, because “Iktos” is a single word that other videos use for other things. We are showing none, because we could not prove any of them are about Iktos.
Official links
Tools that pair well with Iktos
Common stack mates teams adopt alongside Iktos, with the specific reason each pairing earns its keep.
Insilico Medicine
Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.
Recursion
Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.
Nimbus Therapeutics
Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.
Alternatives to Iktos
View all
Insilico Medicine
Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.
Recursion
Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.
Nimbus Therapeutics
Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.
Frequently Asked Questions
Used Iktos? Help shape our editorial sentiment research.